# US 11,992,532 B2 · Hydrogels and methods of using the same > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,992,532 B2 - Document ID: US11992532B2 - Status: Granted - Kind: B2 - Application number: 17/437,579 - Filed: 2020-03-11 - Published: 2022-05-12 - Granted: 2024-05-28 - Earliest claimed: 2019-03-11 - Assignees: The Regents of the University of California; Lankenau Institute for Medical Research - Applicants: The Regents of the University of California; Lankenau Institute for Medical Research - Inventors: Phillip B. Messersmith; Jing Cheng; Ellen Heber-Katz - Web page: https://patentgrep.com/patent/US11992532B2 ## CPC - A61K 47/6903: {the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel} - A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract Disclosed herein are PEG-DPCA conjugates having multiple hydrophobic DPCA groups at one or both terminal ends of a PEG compound and compositions thereof and methods of using thereof for tissue regeneration and/or cellular repair (e.g., wound healing). ## Claims ### Claim 1 A PEG-DPCA conjugate comprising two or more DPCA groups at one terminal end of a PEG compound or at each terminal end of the PEG compound, wherein said PEG-DPCA conjugate has structural Formula I or structural Formula II: wherein n>1. ### Claim 2 (depends on 1) A composition comprising at least one PEG-DPCA conjugate according to claim 1. ### Claim 3 (depends on 1) The PEG-DPCA conjugate according to claim 1, wherein the PEG compound has an average molecular weight of about 250-20,000 Da, about 300-10,000 Da, about 400-9,000 Da, or about 500-8,000 Da. ### Claim 4 (depends on 1) A composition comprising two or more PEG-DPCA conjugates according to claim 1. ### Claim 5 (depends on 2) The composition of claim 2, wherein the composition comprises at least about 1 mg/mL, at least about 3 mg/mL, at least about 5 mg/mL, at least about 8 mg/mL, at least about 10 mg/mL, at least about 11 mg/mL, at least about 15 mg/mL, at least about 20 mg/mL, at least about 32 mg/mL, at least about 39 mg/mL, at least about 48 mg/mL, at least about 59 mg/mL, at least about 66 mg/mL, at least about 76 mg/mL, at least about 88 mg/mL, or at least about 100 mg/mL of the PEG-DPCA conjugate. ### Claim 6 (depends on 5) The composition of claim 5, wherein the conjugate comprises P7D3. ### Claim 7 (depends on 2) The composition of claim 2, wherein the composition comprises at least about 12 mg/mL, at least about 24 mg/mL, at least about 34 mg/mL, at least about 41 mg/mL, at least about 52 mg/mL, at least about 62 mg/mL, at least about 68 mg/mL, at least about 80 mg/mL, at least about 85 mg/mL, at least about 89 mg/mL, at least about 90 mg/mL, at least about 92 mg/mL, at least about 95 mg/mL, at least about 97 mg/mL, at least about 99 mg/mL, or at least about 100 mg/mL of the PEG-DPCA conjugate. ### Claim 8 (depends on 7) The composition of claim 7, wherein the conjugate comprises P80D6. ### Claim 9 (depends on 4) The composition of claim 4, wherein the composition is selected from the group consisting of: a) about 100 mg/mL of the PEG-DPCA conjugate having Structural Formula I and about 0 mg/mL of the PEG-DPCA conjugate having Structural Formula II; b) about 88 mg/mL of the PEG-DPCA conjugate having Structural Formula I and about 12 mg/mL of the PEG-DPCA conjugate having Structural Formula II; c) about 76 mg/mL of the PEG-DPCA conjugate having Structural Formula I and about 24 mg/mL of the PEG-DPCA conjugate having Structural Formula II; d) about 66 mg/mL of the PEG-DPCA conjugate having Structural Formula I and about 34 mg/mL of the PEG-DPCA conjugate having Structural Formula II; e) about 59 mg/mL of the PEG-DPCA conjugate having Structural Formula I and about 41 mg/mL of the PEG-DPCA conjugate having Structural Formula II; f) about 48 mg/mL of the PEG-DPCA conjugate having Structural Formula I and about 52 mg/mL of the PEG-DPCA conjugate having Structural Formula II; g) about 39 mg/mL of the PEG-DPCA conjugate having Structural Formula I and about 61 mg/mL of the PEG-DPCA conjugate having Structural Formula II; h) about 32 mg/mL of the PEG-DPCA conjugate having Structural Formula I and about 68 mg/mL of the PEG-DPCA conjugate having Structural Formula II; i) about 20 mg/mL of the PEG-DPCA conjugate having Structural Formula I and about 80 mg/mL of the PEG-DPCA conjugate having Structural Formula II; j) about 15 mg/mL of the PEG-DPCA conjugate having Structural Formula I and about 85 mg/mL of the PEG-DPCA conjugate having Structural Formula II; k) about 11 mg/mL of the PEG-DPCA conjugate having Structural Formula I and about 89 mg/mL of the PEG-DPCA conjugate having Structural Formula II; l) About 10 mg/mL of the PEG-DPCA conjugate having Structural Formula I and about 90 mg/mL of the PEG-DPCA conjugate having Structural Formula II; m)about 8 mg/mL of the PEG-DPCA conjugate having Structural Formula I and about 92 mg/mL of the PEG-DPCA conjugate having Structural Formula II; n) about 5 mg/mL of the PEG-DPCA conjugate having Structural Formula I and about 95 mg/mL of the PEG-DPCA conjugate having Structural Formula II; o) about 3 mg/mL of the PEG-DPCA conjugate having Structural Formula I and about 97 mg/mL of the PEG-DPCA conjugate having Structural Formula II; p) about 1 mg/mL of the PEG-DPCA conjugate having Structural Formula I and about 99 mg/mL of the PEG-DPCA conjugate having Structural Formula II; and q) about 0 mg/mL of the PEG-DPCA conjugate having Structural Formula I and about 100 mg/mL of the PEG-DPCA conjugate having Structural Formula II. ### Claim 10 (depends on 9) The composition of claim 9, wherein the PEG-DPCA conjugate having Structural Formula I is P7D3 and/or the PEG-DPCA conjugate having Structural Formula II is P80D6.